Earnings Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary. Read the original report. Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn Articles You May Like Skydance’s David Ellison tells CNBC combined company is ‘positioned to win in every single vertical’ Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests CNBC’s Financial Advisor 100 FAQ: Who is eligible and how rankings work PepsiCo cuts earnings forecast as North American turnaround takes longer than expected